Breaking News Instant updates and real-time market news.

VRX

Valeant

$15.37

0.24 (1.59%)

07:08
08/08/17
08/08
07:08
08/08/17
07:08

Valeant reports cash, cash equivalents and restricted cash of $2.025B at June 30

Valeant's cash, cash equivalents and restricted cash were $2.025B at June 30, 2017. The company's availability under the Revolving Credit Facility was approximately $930M at June 30, 2017. Valeant's corporate credit ratings remained unchanged during the second quarter of 2017.

  • 08

    Aug

  • 24

    Aug

VRX Valeant
$15.37

0.24 (1.59%)

07/17/17
WELS
07/17/17
NO CHANGE
WELS
Underperform
Wells says Valeant selling Obagi for less than half of price paid in 2013
After Valeant announced it has agreed to sell its Obagi Medical Products business for $190M in cash, Wells Fargo analyst David Maris noted that this sale price is less than half of the $437M that the company paid to acquire Obagi in April 2013. While Valeant continues to make progress toward its asset sales and debt reduction targets, Maris does not believe that its recent divestitures have had a significant deleveraging impact. He keeps an Underperform rating on Valeant shares.
07/27/17
WELS
07/27/17
NO CHANGE
WELS
Underperform
Doctors not optimistic about Valeant's Siliq, says Wells Fargo
Wells Fargo analyst David Maris says the dozens of doctors he spoke to about Valeant Pharmaceuticals' Siliq are not optimistic. Over 50% of the physicians surveyed said they would use Siliq only as a fourth line therapy or later, Maris tells investors in a research note after Valeant announced the launch of the moderate-to-severe plaque psoriasis treatment. The analyst disagrees with Valeant management's claims that Siliq has "very large peak sales potential." The injection carries a warning about risk of suicide and Valeant will be competing against a large number of peers with greater resources, Maris argues. The analyst has an Underperform rating on Valeant shares, which are down 18c to $17.59 in midday trading.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
08/04/17
WELS
08/04/17
NO CHANGE
WELS
Underperform
Valeant's Isuprel to face generic from Nexus, says Wells Fargo
Wells Fargo analyst David Maris noted that the FDA is reporting, and Nexus Pharmaceuticals has confirmed to him, that the company received approval for a generic version of Valeant's Isuprel. Nexus expects to "command the lion's share" of the U.S. market for the drug, as its version is made in the U.S. and has longer stability than Valeant's version, Maris tells investors. The analyst, who notes that Valeant previously indicated it anticipated that Isuprel would lose exclusivity in Q4, keeps an Underperform rating on the stock.

TODAY'S FREE FLY STORIES

ES

Eversource

$55.59

0.505 (0.92%)

, CTWS

Connecticut Water

$66.09

0.34 (0.52%)

14:23
06/19/18
06/19
14:23
06/19/18
14:23
Hot Stocks
Eversource reiterates Connecticut Water proposal, urges holders vote against SJW »

Eversource Energy (ES)…

ES

Eversource

$55.59

0.505 (0.92%)

CTWS

Connecticut Water

$66.09

0.34 (0.52%)

SJW

SJW Corp.

$67.82

1.31 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
06/19/18
06/19
14:17
06/19/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$146.84

-3.69 (-2.45%)

14:16
06/19/18
06/19
14:16
06/19/18
14:16
Hot Stocks
Whirlpool drops further after AHAM data released »

Shares of Whirlpool have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
06/19/18
06/19
14:16
06/19/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYDY

CytoDyn

$0.00

(0.00%)

14:15
06/19/18
06/19
14:15
06/19/18
14:15
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities Association »

Luncheon Meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ZS

Zscaler

$37.56

-2.8 (-6.94%)

14:15
06/19/18
06/19
14:15
06/19/18
14:15
Options
Zscaler Inc put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

YPF

YPF

$16.57

0.35 (2.16%)

14:05
06/19/18
06/19
14:05
06/19/18
14:05
Options
YPF call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$67.79

-1.96 (-2.81%)

13:55
06/19/18
06/19
13:55
06/19/18
13:55
Options
Xilinx put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$29.19

-0.215 (-0.73%)

13:49
06/19/18
06/19
13:49
06/19/18
13:49
Hot Stocks
Merrill Lynch to pay $42M penalty to settle SEC charges on trade 'masking' »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$195.54

-2.76 (-1.39%)

13:47
06/19/18
06/19
13:47
06/19/18
13:47
Hot Stocks
Facebook takes steps to make video more interactive »

Facebook shares updates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

COTV

Cotiviti Holdings

$44.00

4.105 (10.29%)

13:43
06/19/18
06/19
13:43
06/19/18
13:43
Downgrade
Cotiviti Holdings rating change  »

Cotiviti Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$140.20

34.72 (32.92%)

13:41
06/19/18
06/19
13:41
06/19/18
13:41
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

COTV

Cotiviti Holdings

$44.03

4.14 (10.38%)

13:41
06/19/18
06/19
13:41
06/19/18
13:41
Downgrade
Cotiviti Holdings rating change  »

Cotiviti Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
06/19/18
06/19
13:40
06/19/18
13:40
Options
Alerian MLP attracts a large put buyer »

Alerian MLP attracts a…

FMBH

First Mid-Illinois Bancshares

$41.10

0.25 (0.61%)

13:39
06/19/18
06/19
13:39
06/19/18
13:39
Conference/Events
First Mid-Illinois Bancshares management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 24

    Sep

STE

STERIS

$106.73

-0.82 (-0.76%)

13:37
06/19/18
06/19
13:37
06/19/18
13:37
Conference/Events
STERIS management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

SRPT

Sarepta

$143.85

38.37 (36.38%)

13:35
06/19/18
06/19
13:35
06/19/18
13:35
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

HAIN

Hain Celestial

$29.55

0.69 (2.39%)

13:35
06/19/18
06/19
13:35
06/19/18
13:35
Options
Hain Celestial put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.38

0.175 (0.54%)

, VZ

Verizon

$48.54

1.08 (2.28%)

13:34
06/19/18
06/19
13:34
06/19/18
13:34
Periodicals
AT&T to end sale of user location data to third-party brokers, Verge reports »

AT&T (T) plans to end…

T

AT&T

$32.38

0.175 (0.54%)

VZ

Verizon

$48.54

1.08 (2.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ORCL

Oracle

$46.18

-0.36 (-0.77%)

, MSFT

Microsoft

$100.35

-0.53 (-0.53%)

13:23
06/19/18
06/19
13:23
06/19/18
13:23
Earnings
On The Fly: What to watch for in Oracle's earnings report »

Oracle (ORCL) is…

ORCL

Oracle

$46.18

-0.36 (-0.77%)

MSFT

Microsoft

$100.35

-0.53 (-0.53%)

IBM

IBM

$143.49

-0.96 (-0.66%)

HPE

HP Enterprise

$15.78

-0.14 (-0.88%)

AMZN

Amazon.com

$1,712.48

-11.58 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 10

    Jul

XLU

Utilities SPDR

$49.96

0.27 (0.54%)

13:20
06/19/18
06/19
13:20
06/19/18
13:20
Options
SPDR Repeat put buying in SPDR Utility ETF as the sector sees relative strength »

SPDR Repeat put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:20
06/19/18
06/19
13:20
06/19/18
13:20
General news
Treasury Action: so far there's no sign of a general boycott on Treasuries »

Treasury Action: so far…

SNAP

Snap

$12.95

-1.1 (-7.83%)

13:18
06/19/18
06/19
13:18
06/19/18
13:18
Periodicals
Snap adds to original programming with docu-series, Variety says »

According to Variety,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
06/19/18
06/19
13:17
06/19/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
06/19/18
06/19
13:16
06/19/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.